Page last updated: 2024-12-05

cyproheptadine hydrochloride (anhydrous)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyproheptadine hydrochloride (anhydrous) is a synthetic antihistamine and antiserotonin agent with a wide range of pharmacological effects. It is commonly used to treat allergic reactions, including hay fever, urticaria, and angioedema. Cyproheptadine hydrochloride (anhydrous) is also used to treat migraine headaches and as an appetite stimulant. The synthesis of cyproheptadine hydrochloride (anhydrous) involves a multi-step process that begins with the condensation of 4-chloro-1-phenylpiperidine with 2-methyl-4-phenylquinoline. The resulting product is then reacted with hydrochloric acid to produce the hydrochloride salt. Cyproheptadine hydrochloride (anhydrous) has antihistamine effects by blocking the action of histamine at H1 receptors, which are found in various tissues throughout the body. It also has antiserotonin effects by blocking the action of serotonin at 5-HT2 receptors. These actions contribute to its efficacy in treating allergic reactions and other conditions. Cyproheptadine hydrochloride (anhydrous) has also been studied for its potential to treat other conditions, such as depression, anxiety, and chronic pain. Research continues to explore its therapeutic applications and its role in various physiological processes. '

cyproheptadine hydrochloride (anhydrous) : The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13770
CHEMBL ID1716
CHEBI ID59695
SCHEMBL ID41842

Synonyms (115)

Synonym
AC-15790
MLS001077277
component of dronactin
EU-0100246
969-33-5
cyproheptadine hydrochloride
PRESTWICK_139
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine hydrochloride
cyproheptadine chlorhydrate
cyproheptadine hydrochloride anhydrous
4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine hydrochloride
cyproheptadine hydrochloride (anhydrous)
nsc 169911
vufb3511
piperidine, 4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-, hydrochloride
periactinol (van)
ai3-26940
periactinol hydrochloride
einecs 213-535-1
cpd000058431
antegan
piperidine,d]cyclohepten-5-ylidene)-1-methyl-, hydrochloride
anarexol
cycloheptadine hydrochloride
wln: l c676 byj bu- dt6n dytj a1 &gh
1-methyl-4-(5-dibenzo[a,e]cycloheptatrienylidene)piperidine hydrochloride
cyproheptadine-hydrochloride
periactin hydrochloride
nsc-169911
cyproheptadiene hydrochloride
nuran
cipractin
cypoheptadine hydrochloride
4-(5-dibenzo[a,e]cycloheptatrienylidene)piperidine hydrochloride
nsc169911
cyproheptadine hcl
c21h21n.hcl
smr000058431
MLS000028462 ,
NCGC00093708-02
NCGC00093708-01
4-(5h-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine hydrochloride
MLS002222173
C 6022
CHEMBL1716
nsc-759282
cyproheptadine hydrochloride (anh.)
anhydrous cyproheptadine hydrochloride
4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride
CHEBI:59695 ,
HMS1568E08
sialotin
kyliver
vinorex
contrallerg
istam
kulinet
unii-0s9323mct0
0s9323mct0 ,
MLS001424281
nsc759282
pharmakon1600-01505973
CCG-101144
FT-0603147
LP00246
S2044
AKOS015905305
cyproheptadine hydrochloride [who-dd]
HY-B0366A
cyproheptadine (hydrochloride)
NC00394
SCHEMBL41842
NCGC00260931-01
tox21_500246
REGID_FOR_CID_13770
DTXSID5042586 ,
ZPMVNZLARAEGHB-UHFFFAOYSA-N
W-106308
4-(5h-dibenzo[a,d]cyclohepten-5-ylidine)-methylpiperidine hydrochloride
cyproheptadine (hydrochloride sesquihydrate)
OPERA_ID_383
mfcd00012538
DTXSID70274175 ,
SR-01000003077-9
SR-01000003077-2
SR-01000003077-4
sr-01000003077
SW196450-4
4-(5h-dibenzo [a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride
HB1657
4-(5h-dibenzo[a,d]cyclohepten-5-yli dine)-methylpiperidine hydrochloride
cyproheptadine hydrochloride (periactin)
HMS3678J03
cyproptadine hydrochloride,(s)
Q27126856
AS-14697
C3218
HMS3414J05
BCP34399
C77331
cycloheptadine hcl
1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine;hydrochloride
1-methyl-4-(2-tricyclo[9.4.0.0^{3,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine;hydrochloride
4-(5h-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidinehydrochloride
1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine hydrochloride
dtxcid20196575
cyproheptadine hydrochloride (ep impurity)
4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride
4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride--water (2/3)
cyproheptadine hydrochloride (mart.)
cyproheptadine hydrochloride (usp-rs)
cyproheptadine hydrochloride (usp monograph)
dtxcid3022586
1-methyl-4-{tricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-ylidene}piperidine hydrochloride
EN300-18532506

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency1.00000.180013.557439.8107AID1468
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
beta-2 adrenergic receptorHomo sapiens (human)Potency29.09290.00586.026332.6427AID492947
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency10.00000.01789.637444.6684AID588834
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency24.84460.004611.374133.4983AID624296; AID624297
M-phase phosphoprotein 8Homo sapiens (human)Potency44.66840.177824.735279.4328AID488949
transient receptor potential cation channel subfamily V member 1Homo sapiens (human)Potency12.58930.09120.09120.0912AID488979
lamin isoform A-delta10Homo sapiens (human)Potency11.70310.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID183227Inhibition of bradykinin-induced dermal vascular permeability in rats at a intraperitoneal dose of 100 mg/kg 1 hr prior to challenge1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Drug-induced modifications of the immune response. 12. 4,5-Dihydro-4-oxo-2-(substituted amino)-3-furancarboxylic acids and derivatives as novel antiallergic agents.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1135350Antihistamine activity in ip dosed Duncan-Hartley guinea pig assessed as protection of animal from death caused by histamine aerosol-induced bronchoconstriction1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogues having furan nuclei fused to the 10,11-vinylene bridge.
AID183245Inhibition of histamine -induced dermal vascular permeability in rats at a intraperitoneal dose of 100 mg/kg 1 hr prior to challenge1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Drug-induced modifications of the immune response. 12. 4,5-Dihydro-4-oxo-2-(substituted amino)-3-furancarboxylic acids and derivatives as novel antiallergic agents.
AID183406Inhibition of serotonin -induced dermal vascular permeability in rats at a intraperitoneal dose of 100 mg/kg 1 hr prior to challenge1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Drug-induced modifications of the immune response. 12. 4,5-Dihydro-4-oxo-2-(substituted amino)-3-furancarboxylic acids and derivatives as novel antiallergic agents.
AID1135346Antiserotonin activity in sc dosed Sprague-Dawley rat assessed as inhibition of feet weight gain after 30 mins1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogues having furan nuclei fused to the 10,11-vinylene bridge.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1135348Anticholinergic activity in ip dosed Carworth CF1 mouse assessed as dose required to produce pupil dilation to 1.5 micrometer units in 50% mouse1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogues having furan nuclei fused to the 10,11-vinylene bridge.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (12.50)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's9 (56.25)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.01 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index26.11 (26.88)
Search Engine Supply Index2.25 (0.95)

This Compound (29.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]